Holen Sie sich die Stockscreener-App
4.78
0.42%
-0.02
Handel nachbörslich:
4.81
0.03
+0.63%
Schlusskurs vom Vortag:
$4.80
Offen:
$4.88
24-Stunden-Volumen:
377.79K
Relative Volume:
1.04
Marktkapitalisierung:
$254.77M
Einnahmen:
$17.63M
Nettoeinkommen (Verlust:
$-57.71M
KGV:
-3.2297
EPS:
-1.48
Netto-Cashflow:
$-60.45M
1W Leistung:
-9.13%
1M Leistung:
+9.13%
6M Leistung:
+29.89%
1J Leistung:
-3.04%
1-Tages-Spanne:
$4.69
$4.90
1-Wochen-Bereich:
$4.1325
$5.409
52-Wochen-Spanne:
$1.94
$6.2799
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Firmenname
Scpharmaceuticals Inc
Sektor
Branche
Telefon
617-517-0730
Adresse
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Vergleichen Sie SCPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
4.78 | 255.83M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-07 | Eingeleitet | Craig Hallum | Buy |
| 2022-12-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-10-11 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | Eingeleitet | Maxim Group | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-30 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
Alle ansehen
Scpharmaceuticals Inc Aktie (SCPH) Neueste Nachrichten
Why scPharmaceuticals Inc. stock attracts strong analyst attention2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
What data driven models say about scPharmaceuticals Inc.’s futureJuly 2025 PostEarnings & Consistent Return Investment Signals - Newser
Using R and stats models for scPharmaceuticals Inc. forecasting2025 Year in Review & Fast Entry and Exit Trade Plans - Newser
Is scPharmaceuticals Inc. forming a reversal patternBreakout Watch & Comprehensive Market Scan Reports - Newser
Using R and stats models for scPharmaceuticals Inc. forecasting [Weekly Risk Report]Real-Time Market Sentiment Alerts - Newser
What’s the recovery path for long term holders of scPharmaceuticals Inc.Daily Trade Setup Forecast with Confidence - Newser
Sentiment analysis tools applied to scPharmaceuticals Inc.Portfolio Performance Summary & Short-Term High Return Ideas - Newser
Building trade automation scripts for scPharmaceuticals Inc.Trade Risk Assessment & Proven Capital Preservation Methods - Newser
scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Does scPharmaceuticals Inc. qualify in momentum factor screeningAI Volatility Forecast and Risk Monitor - Newser
Strategies to average down on scPharmaceuticals Inc.Free Swing Setup With Technical Confirmation - Newser
scPharmaceuticals Inc. stock trendline breakdownFree Swing Setup With Technical Confirmation - Newser
Comparing scPharmaceuticals Inc. in custom built stock radarsFree Daily Smart Money Movement Monitor - Newser
Chart based analysis of scPharmaceuticals Inc. trendsLow Exposure Strategy with Sector Analysis - Newser
What earnings revisions data tells us about scPharmaceuticals Inc.Free Watchlist for Smart Swing Trading - Newser
Using data tools to time your scPharmaceuticals Inc. exitFree Watchlist for Low Risk High Return - Newser
How to monitor scPharmaceuticals Inc. with trend dashboardsEntry Optimization Guide with Volume Analysis - Newser
Using Bollinger Bands to evaluate scPharmaceuticals Inc.Real-Time Entry Forecast with Accuracy Metrics - Newser
Wall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to “Hold” - Defense World
Can a trend reversal in scPharmaceuticals Inc. lead to recoveryFree Beginner Friendly Stock Selection Guide - Newser
Analyzing scPharmaceuticals Inc. with multi timeframe chartsShort-Term AI-Based Stock Price Forecast - Newser
What Fibonacci levels say about scPharmaceuticals Inc. reboundVolume Confirmed Setup with Entry Confidence - Newser
How scPharmaceuticals Inc. stock performs during market volatility [Gold Moves]Long Hold Capital Preservation Plans - Newser
What institutional flow reveals about scPharmaceuticals Inc.Free Market Surge Signal for Swing Traders - Newser
What makes scPharmaceuticals Inc. stock price move sharplyTop Stock Picks with Forecast Accuracy - Newser
Identifying reversal signals in scPharmaceuticals Inc.Long Term Stock Growth Plan Suggestions - Newser
Analyzing net buyer seller activity in scPharmaceuticals Inc.AI-Powered Stock Trend Movement Analysis - Newser
scPharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsFree Fast Entry High Potential Stock Alerts - Newser
ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025 - MSN
Strong Financial Performance and Strategic Initiatives Justify Buy Rating for scPharmaceuticals - TipRanks
Is scPharmaceuticals Inc. stock bottoming outFree Real Market Momentum Signal Generator - Newser
Scpharmaceuticals 2025 Q2 Earnings Loss Narrows Despite Revenue Surge - AInvest
SCPH Revenue Up 99% - AOL.com
scPharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
scPharmaceuticals Inc (SCPH) Q2 2025 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Promising Outlook for scPharmaceuticals: Buy Rating Supported by Strong Furoscix Demand and Strategic Growth Initiatives - TipRanks
scPharmaceuticals reports Q2 EPS (34c), consensus (30c) - TipRanks
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Scpharmaceuticals earnings missed by $0.05, revenue topped estimates - Investing.com Australia
ScPharmaceuticals Q2 revenue beats expectations, Furoscix approval expands to chronic kidney disease patients. - AInvest
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - The Globe and Mail
Momentum divergence signals in scPharmaceuticals Inc. chartFree Weekly Potential Breakout Stock List - Newser
Finanzdaten der Scpharmaceuticals Inc-Aktie (SCPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):